litlas
Log inCreate account

Lauren E. Abrey

Active 1998–2022

97
Papers
22,835
Citations
82
h-index
97
i10-index

Citations

Citations per year for Lauren E. Abrey1999: 7 citations2000: 10 citations2001: 11 citations2002: 26 citations2003: 32 citations2004: 38 citations2005: 48 citations2006: 77 citations2007: 116 citations2008: 144 citations2009: 228 citations2010: 284 citations2011: 278 citations2012: 233 citations2013: 223 citations2014: 261 citations2015: 251 citations2016: 235 citations2017: 268 citations2018: 208 citations2019: 576 citations2020: 684 citations2021: 583 citations2022: 412 citations2023: 315 citations2024: 427 citations2025: 164 citations2026: 5 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,918 citing papers, 30.6% of this breakdownGermany: 529 citing papers, 8.5% of this breakdownChina: 412 citing papers, 6.6% of this breakdownUnited Kingdom: 330 citing papers, 5.3% of this breakdownFrance: 322 citing papers, 5.1% of this breakdownItaly: 322 citing papers, 5.1% of this breakdownSwitzerland: 266 citing papers, 4.2% of this breakdownNetherlands: 241 citing papers, 3.8% of this breakdownCanada: 198 citing papers, 3.2% of this breakdownJapan: 167 citing papers, 2.7% of this breakdownSpain: 142 citing papers, 2.3% of this breakdownAustralia: 135 citing papers, 2.2% of this breakdown
0%30.6%Other 20.4%

Institutions

Fields

  • Medicine78.9%
  • Biochemistry, Genetics and Molecular Biology11.2%
  • Neuroscience2.8%
  • Immunology and Microbiology2.7%
  • Materials Science1.4%
  • Engineering1.1%
  • Other1.9%

Topics

  • Glioma Diagnosis and Treatment19.3%
  • Brain Metastases and Treatment7.9%
  • CNS Lymphoma Diagnosis and Treatment4.9%
  • Lymphoma Diagnosis and Treatment4.2%
  • Meningioma and schwannoma management2.7%
  • Cancer, Hypoxia, and Metabolism2.3%
  • Other58.7%

Coauthors

All papers

Open in search
  1. Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

    Authors: Olivier Chinot, Wolfgang Wick, Warren Mason, Roger Henriksson, Frank Saran, Ryo Nishikawa, Alain Carpentier, Khê Hoang‐Xuan, Petr Kavan, Dana Cernea, Alba A. Brandes, Magalie Hilton, Lauren E. Abrey, Timothy F. Cloughesy - New England Journal of Medicine 2014 cited by 2,503

  2. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

    Authors: Henry S. Friedman, Michael D. Prados, Patrick Y. Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, W.K. Alfred Yung, Nina A. Paleologos, M. Kelly Nicholas, Randy L. Jensen, James J. Vredenburgh, Jane Huang, Maoxia Zheng, Timothy F. Cloughesy - Journal of Clinical Oncology 2009 cited by 2,444

  3. Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma

    Authors: Lauren E. Abrey, Tracy T. Batchelor, Andrés J.M. Ferreri, Mary Gospodarowicz, Elisa Jacobsen Pulczynski, Emanuele Zucca, Justine R. Smith, Agnieszka Korfel, Carole Soussain, Lisa M. DeAngelis, Edward A. Neuwelt, Brian Patrick O’Neill, Eckhard Thiel, Tamara Shenkier, Francesc Graus, Martin J. van den Bent, John F. Seymour, Philip Poortmans, Jamés O. Armitage, Franco Cavalli - Journal of Clinical Oncology 2005 cited by 906

  4. Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model

    Authors: Lauren E. Abrey, Leah Ben‐Porat, Katherine S. Panageas, Joachim Yahalom, Brian Berkey, Walter J. Curran, Christopher J. Schultz, Steven A. Leibel, Diana F. Nelson, Minesh P. Mehta, Lisa M. DeAngelis - Journal of Clinical Oncology 2006 cited by 620

  5. Leveraging external data in the design and analysis of clinical trials in neuro-oncology

    Authors: Rifaquat Rahman, Steffen Ventz, Jon McDunn, Bill Louv, Irmarie Reyes‐Rivera, Mei‐Yin C. Polley, Fahar Merchant, Lauren E. Abrey, Joshua E. Allen, Laura K. Aguilar, Estuardo Aguilar-Córdova, David Arons, Kirk Tanner, Stephen Bagley, Mustafa Khasraw, Timothy F. Cloughesy, Patrick Y. Wen, Brian M. Alexander, Lorenzo Trippa - The Lancet Oncology 2021 cited by 84

  6. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma

    Authors: Antonio Omuro, Denise D. Correa, Lisa M. DeAngelis, Craig H. Moskowitz, Matthew J. Matasar, Thomas Kaley, Igor T. Gavrilovic, Craig Nolan, Elena Pentsova, Christian Grommes, Katherine S. Panageas, Raymond E. Baser, Géraldine Faivre, Lauren E. Abrey, Craig S. Sauter - Blood 2015 cited by 345

  7. Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome

    Authors: Patrick G. Morris, Denise D. Correa, Joachim Yahalom, Jeffrey J. Raizer, David Schiff, Barbara Grant, Sean Grimm, Rose Lai, Anne S. Reiner, K. Panageas, Sasan Karimi, Richard Curry, Gaurav Shah, Lauren E. Abrey, Lisa M. DeAngelis, Antonio Omuro - Journal of Clinical Oncology 2013 cited by 491

  8. Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

    Authors: Kathleen R. Lamborn, W.K. Alfred Yung, Susan M. Chang, Patrick Y. Wen, Timothy F. Cloughesy, Lisa M. DeAngelis, H. Ian Robins, Frank S. Lieberman, Howard A. Fine, Karen Fink, Larry Junck, Lauren E. Abrey, Mark R. Gilbert, Minesh P. Mehta, John G. Kuhn, Kenneth Aldape, Janelle L. Hibberts, Pamela Peterson, Michael D. Prados - Neuro-Oncology 2008 cited by 422

  9. Strategies to advance translational research into brain barriers

    Authors: Edward A. Neuwelt, N. Joan Abbott, Lauren E. Abrey, William A. Banks, Brian W. Blakley, Thomas P. Davis, Britta Engelhardt, Paula Grammas, Maiken Nedergaard, John G. Nutt, William M. Pardridge, Gary A. Rosenberg, Quentin R. Smith, Lester R. Drewes - The Lancet Neurology 2008 cited by 469

  10. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

    Authors: Thomas Sandmann, Richard Bourgon, Josep Garcia, Congfen Li, Timothy F. Cloughesy, Olivier Chinot, Wolfgang Wick, Ryo Nishikawa, Warren Mason, Roger Henriksson, Frank Saran, Albert Lai, N. Moore, Samir Kharbanda, Franklin Peale, Priti S. Hegde, Lauren E. Abrey, Heidi Phillips, Carlos Bais - Journal of Clinical Oncology 2015 cited by 293

  11. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma

    Authors: Thomas Kaley, Patrick Y. Wen, David Schiff, Keith L. Ligon, Sam Haidar, Sasan Karimi, Andrew B. Lassman, Craig Nolan, Lisa M. DeAngelis, Igor T. Gavrilovic, Andrew D. Norden, Jan Drappatz, Eudocia Q. Lee, Benjamin Purow, Scott R. Plotkin, Tracy T. Batchelor, Lauren E. Abrey, Antonio Omuro - Neuro-Oncology 2014 cited by 289

  12. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)

    Authors: Fábio M. Iwamoto, Kathleen R. Lamborn, H. I. Robins, Minesh P. Mehta, Shannon Chang, Nicholas Butowski, Lisa M. DeAngelis, Lauren E. Abrey, Wei Zhang, Michael D. Prados, H. A. Fine - Neuro-Oncology 2010 cited by 219

  13. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma

    Authors: Thomas Kaley, Katherine S. Panageas, Ingo K. Mellinghoff, Craig Nolan, Igor T. Gavrilovic, Lisa M. DeAngelis, Lauren E. Abrey, Eric C. Holland, Andrew B. Lassman - Journal of Neuro-Oncology 2019 cited by 62

  14. Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma

    Authors: Jacques Grill, Maura Massimino, Éric Bouffet, Amedeo A. Azizi, Geoffrey McCowage, Adela Cañete, Frank Saran, Marie‐Cécile Le Deley, Pascale Varlet, Paul S. Morgan, Tim Jaspan, Chris Jones, Felice Giangaspero, Helen Smith, Josep Garcia, Markus C. Elze, Raphaël F. Rousseau, Lauren E. Abrey, Darren Hargrave, Gilles Vassal - Journal of Clinical Oncology 2018 cited by 140

  15. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma

    Authors: Benjamin M. Ellingson, Lauren E. Abrey, Sarah J. Nelson, Timothy J. Kaufmann, Josep Garcia, Olivier Chinot, Frank Saran, Ryo Nishikawa, Roger Henriksson, W. P. Mason, Wolfgang Wick, Nicholas Butowski, Keith L. Ligon, Elizabeth R. Gerstner, Howard Colman, John de Groot, Susan M. Chang, Ingo K. Mellinghoff, Robert J. Young, Brian M. Alexander, Rivka R. Colen, Jennie Taylor, Isabel Arrillaga‐Romany, Arnav Mehta, Raymond Y. Huang, Whitney B. Pope, David A. Reardon, Tracy T. Batchelor, Michael D. Prados, Evanthia Galanis, Patrick Y. Wen, Timothy F. Cloughesy - Neuro-Oncology 2018 cited by 96

  16. Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma

    Authors: Thomas Kaley, Katherine S. Panageas, Elena Pentsova, Ingo K. Mellinghoff, Craig Nolan, Igor T. Gavrilovic, Lisa M. DeAngelis, Lauren E. Abrey, Eric C. Holland, Antonio Omuro, Mario E. Lacouture, Emmy Ludwig, Andrew B. Lassman - Annals of Clinical and Translational Neurology 2020 cited by 46

  17. Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma

    Authors: Gaurav Shah, Joachim Yahalom, Denise D. Correa, Rose Lai, Jeffrey J. Raizer, David Schiff, Renato V. LaRocca, Barbara Grant, Lisa M. DeAngelis, Lauren E. Abrey - Journal of Clinical Oncology 2007 cited by 403

  18. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab

    Authors: Patrick Großmann, Vivek Narayan, Ken Chang, Rifaquat Rahman, Lauren E. Abrey, David A. Reardon, Lawrence H. Schwartz, Patrick Y. Wen, Brian M. Alexander, Raymond Y. Huang, Hugo J.W.L. Aerts - Neuro-Oncology 2017 cited by 111

  19. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial

    Authors: Hans‐Georg Wirsching, Ghazaleh Tabatabai, Ulrich Roelcke, Andreas F. Hottinger, Francisca Jörger, Andrea Schmid, Ludwig Plaßwilm, Daniel Schrimpf, Christoph Mancao, David Capper, Katrin Conen, Thomas Hundsberger, Francesca Caparrotti, Roger von Moos, Christian Riklin, Jörg Felsberg, Patrick Roth, David Jones, Stefan M. Pfister, Elisabeth J. Rushing, Lauren E. Abrey, Guido Reifenberger, Leonhard Held, Andreas von Deimling, Adrian F. Ochsenbein, Michael Weller - Annals of Oncology 2018 cited by 86

  20. Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

    Authors: Philip H. Gutin, Fábio M. Iwamoto, Kathryn Beal, Nimish Mohile, Sasan Karimi, Bob L. Hou, Stella Lymberis, Yoshiya Yamada, Jenghwa Chang, Lauren E. Abrey - International Journal of Radiation Oncology*Biology*Physics 2009 cited by 373

  21. Phase I Study of Intraventricular Administration of Rituximab in Patients With Recurrent CNS and Intraocular Lymphoma

    Authors: James L. Rubenstein, Jane Fridlyand, Lauren E. Abrey, Arthur Shen, Jon Karch, Endi Wang, Samar Issa, Lloyd E. Damon, Michael D. Prados, Michael McDermott, Joan M. O’Brien, Chris Haqq, Marc Shuman - Journal of Clinical Oncology 2007 cited by 325

  22. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report

    Authors: Sean Grimm, José S. Pulido, Kristoph Jahnke, David Schiff, Anthony Hall, Tamara Shenkier, T. Siegal, Nancy D. Doolittle, Tracy T. Batchelor, Ulrich Herrlinger, Edward A. Neuwelt, Normand Laperrière, Marc C. Chamberlain, Jean‐Yves Blay, Andrés J.M. Ferreri, Antonio Omuro, E. Thiel, Lauren E. Abrey - Annals of Oncology 2007 cited by 287

  23. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma

    Authors: Andrew D. Norden, Jeffrey J. Raizer, Lauren E. Abrey, Kathleen R. Lamborn, Andrew B. Lassman, Susan M. Chang, W.K. Alfred Yung, Mark R. Gilbert, Howard A. Fine, Minesh P. Mehta, Lisa M. DeAngelis, Timothy F. Cloughesy, H. Ian Robins, Kenneth Aldape, Janet Dancey, Michael D. Prados, Frank S. Lieberman, Patrick Y. Wen - Journal of Neuro-Oncology 2009 cited by 196

  24. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials

    Authors: Kelong Han, Min Ren, Wolfgang Wick, Lauren E. Abrey, Arabinda K. Das, James Jin, David A. Reardon - Neuro-Oncology 2013 cited by 142